Editorials

 2011 
 2010 
 2009 
 2008 
 2007 
 2006 
 2005 
 2004 
 2003 
 2002 
 2001 
 2000 
 1999 


2012

  • Yes! Statins can be given to liver patients
    February 2012 (Vol. 56 | No. 2 | Pages 305-307)

    Ted Bader

  • NKG2D and its ligands: Key to immunotherapy of liver cancer?
    February 2012 (Vol. 56 | No. 2 | Pages 308-310)

    Mario U. Mondelli

  • HIF-1α is a major and complex player in alcohol induced liver diseases
    February 2012 (Vol. 56 | No. 2 | Pages 311-312)

    Wajahat Z. Mehal

  • The Journal of Hepatology: An international journal in a new era
    January 2012 (Vol. 56 | No. 1 | Page 4)

    Didier Samuel

  • Get Active
    January 2012 (Vol. 56 | No. 1 | Pages 5-6)

    Mark Thursz

  • IL-33 – A cytokine which balances on a knife’s edge?
    January 2012 (Vol. 56 | No. 1 | Pages 7-10)

    Annette Erhardt, Gisa Tiegs

  • The invaders and the barrier
    January 2012 (Vol. 56 | No. 1 | Pages 11-13)

    Jean-Michel Pawlotsky

  • Salvage liver transplantation for recurrent hepatocellular carcinoma after radiofrequency ablation: A new strategy?
    January 2012 (Vol. 56 | No. 1 | Pages 14-16)

    Robin K. Kelley, Francis Yao

  • Who pulls the trigger: JNK activation in liver lipotoxicity?
    January 2012 (Vol. 56 | No. 1 | Pages 17-19)

    Samar H. Ibrahim, Gregory J. Gores

  • Chronic intermittent hypoxia: A breath of fresh air in the understanding of NAFLD pathogenesis
    January 2012 (Vol. 56 | No. 1 | Pages 20-22)

    Maud Lemoine, Lawrence Serfaty

  • Touching some firm ground in the epidemiology of NASH
    January 2012 (Vol. 56 | No. 1 | Pages 23-25)

    Vlad Ratziu, Mihai Voiculescu, Thierry Poynard

2011

  • HBV treatment and pregnancy
    December 2011 (Vol. 55 | No. 6 | Pages 1171-1173)

    Jörg Petersen

  • Vascular invasion leaves its mark in hepatocellular carcinoma
    December 2011 (Vol. 55 | No. 6 | Pages 1174-1175)

    Aileen Marshall, Graeme Alexander

  • Autophagy and hepatic stellate cell activation – Partners in crime?
    December 2011 (Vol. 55 | No. 6 | Pages 1176-1177)

    Christine C. Hsu, Robert F. Schwabe

  • A major step towards effective treatment evaluation in primary biliary cirrhosis
    December 2011 (Vol. 55 | No. 6 | Pages 1178-1180)

    Ulrich Beuers, Keith D. Lindor

  • Evaluation of the gut barrier to intestinal bacteria in non-alcoholic fatty liver disease
    December 2011 (Vol. 55 | No. 6 | Pages 1181-1183)

    Andrea De Gottardi, Kathy D. McCoy

  • APOC3 polymorphisms and non-alcoholic fatty liver disease: Resolving some doubts and raising others
    December 2011 (Vol. 55 | No. 6 | Pages 1184-1186)

    Manuel Romero-Gómez

  • Soft technique, hard end-points
    November 2011 (Vol. 55 | No. 5 | Pages 955-956)

    Jaume Bosch

  • Targeting STAT3 in hepatocellular carcinoma: Sorafenib again…
    November 2011 (Vol. 55 | No. 5 | Pages 957-959)

    Olivier Rosmorduc, Christèle Desbois-Mouthon

  • IL-1 cytokine family members and NAFLD: Neglected in metabolic liver inflammation
    November 2011 (Vol. 55 | No. 5 | Pages 960-962)

    Herbert Tilg, Alexander R. Moschen

  • β-Blockers and refractory ascites in cirrhosis: The message of a team of true scientists
    October 2011 (Vol. 55 | No. 4 | Pages 743-744)

    Paolo Angeli

  • DCD donors: A unique source to significantly increase organ donation
    October 2011 (Vol. 55 | No. 4 | Pages 745-746)

    Juan C. García-Valdecasas

  • Drug induced liver injury and its relationship to autoimmune hepatitis
    October 2011 (Vol. 55 | No. 4 | Pages 747-749)

    Christina Weiler-Normann, Christoph Schramm

  • A potential retroviral aetiology for mouse PBC: More answers or more questions?
    October 2011 (Vol. 55 | No. 4 | Pages 750-752)

    David E.J. Jones

  • Polymorphism of methylenetetrahydrofolate reductase as disease modifier – A déjà-vu in Wilson disease?
    October 2011 (Vol. 55 | No. 4 | Pages 753-755)

    Peter Ferenci

  • Chronic hepatitis C genotype 2 and 3: Are we ready for personalized medicine?
    September 2011 (Vol. 55 | No. 3 | Pages 505-506)

    Maya Gambarin-Gelwan, Ira M. Jacobson

  • Individualizing hepatitis B infection prophylaxis in liver transplant recipients
    September 2011 (Vol. 55 | No. 3 | Pages 507-509)

    Alyson N. Fox, Norah A. Terrault

  • Role of mycophenolate mofetil in the treatment of autoimmune hepatitis
    September 2011 (Vol. 55 | No. 3 | Pages 510-511)

    Christoph Schramm, Ansgar W. Lohse

  • NK cells in acute hepatitis C
    August 2011 (Vol. 55 | No. 2 | Pages 265-267)

    Jacob Nattermann

  • Pharmacological management of hepatorenal syndrome: Lessons from non-responders
    August 2011 (Vol. 55 | No. 2 | Pages 268-269)

    Pere Ginès

  • Genomic medicine reaches HCV-related liver transplantation: Hopes and clinical and public health implications
    August 2011 (Vol. 55 | No. 2 | Pages 270-272)

    F. Xavier López-Labrador, Marina Berenguer

  • Shedding new light on vitamin D and fatty liver disease
    August 2011 (Vol. 55 | No. 2 | Pages 273-275)

    Andreas Geier

  • Fighting the bushfire in HCC trials
    August 2011 (Vol. 55 | No. 2 | Pages 276-277)

    Peter Schirmacher, Pierre Bedossa, Tania Roskams, Dina G. Tiniakos, Elizabeth M. Brunt, Jessica Zucman-Rossi, Michael P. Manns, Peter R. Galle

  • Prediction of fibrosis progression in hepatitis C infection: Are genetics ready for clinical use?
    July 2011 (Vol. 55 | No. 1 | Pages 3-4)

    Hermann E. Wasmuth, Christian Trautwein

  • Prediction of fibrosis progression in hepatitis C infection: Are genetics ready for clinical use?
    July 2011 (Vol. 55 | No. 1 | Pages 3-4)

    Hermann E. Wasmuth, Christian Trautwein

  • Will the pathomolecular classification of hepatocellular adenomas improve their clinical management?
    July 2011 (Vol. 55 | No. 1 | Pages 8-10)

    Paulette Bioulac-Sage, Charles Balabaud, Jessica Zucman-Rossi

  • New protease inhibitors for HCV – Help is on the way
    June 2011 (Vol. 54 | No. 6 | Pages 1087-1089)

    Dahlene N. Fusco, Raymond T. Chung

  • No need for a large belly to have NASH
    June 2011 (Vol. 54 | No. 6 | Pages 1090-1093)

    Mariana Verdelho Machado, Helena Cortez-Pinto

  • Insights into the role of interferon lambda in hepatitis C virus infection
    May 2011 (Vol. 54 | No. 5 | Pages 844-847)

    Heidi Barth

  • Evaluation of combination therapy against hepatitis C virus infection in human liver chimeric mice
    May 2011 (Vol. 54 | No. 5 | Pages 848-850)

    Ype P. de Jong, Charles M. Rice, Alexander Ploss

  • Adipose-tissue derived hepatic stem cells for gene therapy: Fat goes to liver’s rescue?
    May 2011 (Vol. 54 | No. 5 | Pages 851-852)

    Nicolas Ferry

  • The inflammatory microenvironment of HCC – The plot becomes complex
    May 2011 (Vol. 54 | No. 5 | Pages 853-855)

    Jörg Schrader, John P. Iredale

  • UDCA for NASH: End of the story?
    May 2011 (Vol. 54 | No. 5 | Pages 856-858)

    Marion Haedrich, Jean-François Dufour

  • Herbal medicine hepatotoxicity: A new step with development of specific biomarkers
    April 2011 (Vol. 54 | No. 4 | Pages 599-601)

    Dominique Larrey, Stéphanie Faure

  • Methylation profile as a new tool for classification of hepatocellular carcinoma
    April 2011 (Vol. 54 | No. 4 | Pages 602-603)

    Christine Perret

  • The quest for equity in liver transplantation: Another lesson learned from women
    March 2011 (Vol. 54 | No. 3 | Pages 401-402)

    François Durand

  • Long distance calling for liver regeneration: Identification of neuroendocrine signalling pathways activated after partial hepatectomy
    March 2011 (Vol. 54 | No. 3 | Pages 403-405)

    Matías A. Avila

  • Regulation of the expression of the hepatocellular sulfate–oxalate exchanger SAT-1 (SLC26A1) by glyoxylate: A metabolic link between liver and kidney?
    March 2011 (Vol. 54 | No. 3 | Pages 406-407)

    Bruno Stieger

  • The GAPs between hepatocellular carcinoma and RAS
    February 2011 (Vol. 54 | No. 2 | Pages 191-192)

    Luis Miguel Guachalla, K. Lenhard Rudolph

  • Recognizing autoimmune hepatitis: Scores help, but no more
    February 2011 (Vol. 54 | No. 2 | Pages 193-194)

    Ansgar W. Lohse

  • First year and beyond
    January 2011 (Vol. 54 | No. 1 | Page 3)

    Didier Samuel

  • From volcano clouds to iLivers: EASL growing in times of change
    January 2011 (Vol. 54 | No. 1 | Pages 4-5)

    Heiner Wedemeyer

  • From volcano clouds to iLivers: EASL growing in times of change
    January 2011 (Vol. 54 | No. 1 | Pages 4-5)

    Heiner Wedemeyer

  • Hepatitis E: Water, water everywhere – Now a Global Disease
    January 2011 (Vol. 54 | No. 1 | Pages 9-11)

    Subrat Kumar Acharya, Subrat Kumar Panda

2010

  • Increased iron in HCV infection: Collateral damage or antiviral defense?
    December 2010 (Vol. 53 | No. 6 | Pages 990-992)

    Sebastian Mueller

  • Drug-induced liver injury: Is it time for genetics to change our clinical practice?
    December 2010 (Vol. 53 | No. 6 | Pages 993-994)

    Pietro Invernizzi

  • Renal sodium retention in pre-ascitic cirrhosis: The more we know about the puzzle, the more it becomes intricate
    November 2010 (Vol. 53 | No. 5 | Pages 790-792)

    Mauro Bernardi, Luca Santi

  • Dissecting the evolutionary genetics of iron overload in non-alcoholic fatty liver disease
    November 2010 (Vol. 53 | No. 5 | Pages 793-794)

    Felix Stickel, Jochen Hampe

  • Fibroblast growth factor 21 as a biomarker for NAFLD: Integrating pathobiology into clinical practice
    November 2010 (Vol. 53 | No. 5 | Pages 795-796)

    Gareth Morris-Stiff, Ariel E. Feldstein

  • Prognosis indicator in acute liver failure: Is there a place for cell death markers?
    October 2010 (Vol. 53 | No. 4 | Pages 593-595)

    Didier Samuel, Philippe Ichai

  • Exploiting liver immunity for the prevention of hepatic metastases
    October 2010 (Vol. 53 | No. 4 | Pages 596-598)

    Licia Rivoltini, Vincenzo Mazzaferro

  • Is there an ideal prognostic classification for hepatocellular carcinoma? The quest for the Holy Grail
    July 2010 (Vol. 53 | No. 1 | Pages 23-24)

    Jean-Claude Trinchet, Michel Beaugrand

  • Renal function and MELD: Being direct is better
    May 2010 (Vol. 52 | No. 5 | Pages 622-623)

    Stevan A. Gonzalez, James F. Trotter

  • Treating hepatitis C in patients with cirrhosis: The effort is worth it
    May 2010 (Vol. 52 | No. 5 | Pages 624-626)

    Xavier Forns, Jordi Bruix

  • Re-emerging interest in hepatitis delta: New insights into the dynamic interplay between HBV and HDV
    May 2010 (Vol. 52 | No. 5 | Pages 627-629)

    Heiner Wedemeyer

  • Are viral or host factors predictive of response to interferon–ribavirin in transplant patients with hepatitis C?
    May 2010 (Vol. 52 | No. 5 | Pages 630-632)

    Bruno Roche, Didier Samuel

  • New therapeutic targets in HCC: Reptin ATPase and HCC senescence
    May 2010 (Vol. 52 | No. 5 | Pages 633-634)

    Carmen Berasain

  • Ribavirin ante portas: Uptake transporters into hepatocytes dissected
    April 2010 (Vol. 52 | No. 4 | Pages 469-471)

    Bertram Bengsch, Robert Thimme

  • Treatment of chronic hepatitis C in children: Is it necessary and, if so, in whom?
    April 2010 (Vol. 52 | No. 4 | Pages 472-474)

    Anna Alisi, Donatella Comparcola, Valerio Nobili

  • A new role for an old marker, HBsAg
    April 2010 (Vol. 52 | No. 4 | Pages 475-477)

    Maurizia Rossana Brunetto

  • Entecavir in decompensated HBV cirrhosis: The future is looking brighter
    February 2010 (Vol. 52 | No. 2 | Pages 147-149)

    Robert J. Fontana

  • Will nano-fibers permit to turn liver cell transplantation into a curative tool against liver failure?
    February 2010 (Vol. 52 | No. 2 | Pages 150-152)

    Nicolas Moniaux, Jamila Faivre

  • Welcome editorial
    January 2010 (Vol. 52 | No. 1 | Pages 5-6)

    Didier Samuel

  • Secondary peritonitis in cirrhosis: “Oil in fire”
    January 2010 (Vol. 52 | No. 1 | Pages 7-9)

    Reiner Wiest, Juergen Schoelmerich

2009

  • Welcome editorial
    January 2010 (Vol. 52 | No. 1 | Pages 5-6)

    Didier Samuel

  • Secondary peritonitis in cirrhosis: “Oil in fire”
    January 2010 (Vol. 52 | No. 1 | Pages 7-9)

    Reiner Wiest, Juergen Schoelmerich

  • Early prediction of encephalopathy in hospitalized patients with severe acute liver disease: The narrow window of opportunity for transplant-free survival
    December 2009 (Vol. 51 | No. 6 | Pages 977-980)

    Jacques Bernuau, François Durand

  • Transarterial therapies in HCC: Does embolization increase survival?
    December 2009 (Vol. 51 | No. 6 | Pages 981-983)

    Alejandro Forner, Jean-Claude Trinchet

  • Hepatitis C after simultaneous liver–kidney transplantation
    November 2009 (Vol. 51 | No. 5 | Pages 839-841)

    Andreas Cerny

  • Risk of recurrence in hepatitis B-related hepatocellular carcinoma: Impact of viral load in late recurrence
    November 2009 (Vol. 51 | No. 5 | Pages 842-844)

    Yujin Hoshida

  • Cost-effectiveness of oral treatments for chronic hepatitis B
    October 2009 (Vol. 51 | No. 4 | Pages 623-625)

    Geoffrey M. Dusheiko

  • Forewarned is forearmed
    October 2009 (Vol. 51 | No. 4 | Pages 626-627)

    Stefan Zeuzem

  • HCV reinfection studies and the door to vaccine development
    October 2009 (Vol. 51 | No. 4 | Pages 628-631)

    Jason Grebely, David L. Thomas, Gregory J. Dore

  • Portal vein thrombosis: A predictable milestone in cirrhosis?
    October 2009 (Vol. 51 | No. 4 | Pages 632-634)

    Juan Carlos Garcia-Pagan, Dominique-Charles Valla

  • Requiem for a champion? Living donor liver transplantation
    October 2009 (Vol. 51 | No. 4 | Pages 635-637)

    Pierre-Alain Clavien, Philipp Dutkowski, James F. Trotter

  • Show me your signaling– and I’ll tell you who you are
    October 2009 (Vol. 51 | No. 4 | Pages 638-639)

    Jörn M. Schattenberg, Peter R. Galle

  • New insights into hepatitis B and C virus co-infection
    September 2009 (Vol. 51 | No. 3 | Pages 423-425)

    Volker Brass, Darius Moradpour

  • Infection and inflammation in liver failure: Two sides of the same coin
    September 2009 (Vol. 51 | No. 3 | Pages 426-429)

    Raza Malik, Rajeshwar P. Mookerjee, Rajiv Jalan

  • Cigarette smoke exposure: A novel cofactor of NAFLD progression?
    September 2009 (Vol. 51 | No. 3 | Pages 430-432)

    Ariane Mallat, Sophie Lotersztajn

  • A short cut to predict the clinical response to beta-blocker therapy in cirrhosis?
    August 2009 (Vol. 51 | No. 2 | Pages 268-270)

    Carlo Merkel

  • Treatment with nucleos(t)ide analogues in chronic hepatitis B: Where does the road map lead us?
    July 2009 (Vol. 51 | No. 1 | Pages 1-3)

    Harry L.A. Janssen, Jurriën G.P. Reijnders

  • What offers the best prediction of sustained virologic response during combination therapy with interferon and ribavirin: Viral dynamics, viral levels at certain time points, or a combination of both?
    July 2009 (Vol. 51 | No. 1 | Pages 4-7)

    Ola Weiland

  • Mycophenolate mofetil to the rescue in autoimmune hepatitis: A fresh sprout on the decision tree
    July 2009 (Vol. 51 | No. 1 | Pages 8-10)

    Albert J. Czaja

  • Vitamin D receptor polymorphisms in primary biliary cirrhosis: A functional connection?
    June 2009 (Vol. 50 | No. 6 | Pages 1071-1073)

    Luciano Adorini

  • Hepatitis C virus and its complex interplay with hepatic glucose and lipid metabolism
    May 2009 (Vol. 50 | No. 5 | Pages 845-847)

    Birke Bartosch

  • Portal hypertension and development of hepatocellular carcinoma: Factors influencing significance in prognostic models
    May 2009 (Vol. 50 | No. 5 | Pages 848-849)

    Erik Christensen

  • Clinical research in hepatocellular carcinoma: Study design and endpoints
    May 2009 (Vol. 50 | No. 5 | Pages 850-853)

    Alejandro Forner, Sasan Roayaie

  • Prevention of hepatocellular carcinoma: The holy grail of hepatitis B treatment
    May 2009 (Vol. 50 | No. 5 | Pages 854-856)

    Morris Sherman

  • Uncoupling proteins and non-alcoholic fatty liver disease
    May 2009 (Vol. 50 | No. 5 | Pages 857-860)

    Helena Cortez-Pinto, Mariana V. Machado

  • Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practice
    April 2009 (Vol. 50 | No. 4 | Pages 644-647)

    Pietro Lampertico

  • Insulin resistance in HCV mono-infected and in HIV/HCV co-infected patients: Looking to the future
    April 2009 (Vol. 50 | No. 4 | Pages 648-651)

    Calogero Cammà, Salvatore Petta

  • Antiviral therapy in HCV-infected cirrhotics awaiting liver transplantation: A costly strategy for mixed virological results
    April 2009 (Vol. 50 | No. 4 | Pages 652-654)

    Bruno Roche, Didier Samuel

  • Hepatocellular carcinoma in HIV-infected patients comes of age: The convergence of epidemiology and treatment effectiveness
    April 2009 (Vol. 50 | No. 4 | Pages 655-658)

    Mark Sulkowski

  • Modern diagnosis of hepatocellular carcinoma: Utilization of liver biopsy and genomic markers
    April 2009 (Vol. 50 | No. 4 | Pages 659-661)

    Jorge A. Marrero

  • Regulation of hepatitis C virus replication by microRNAs
    March 2009 (Vol. 50 | No. 3 | Pages 441-444)

    Thomas Pietschmann

  • Genetic variability of hepatitis B virus and response to antiviral treatments: Searching for a bigger picture
    March 2009 (Vol. 50 | No. 3 | Pages 445-448)

    Lilly K.W. Yuen, Stephen A. Locarnini

  • Role of genotyping in Wilson’s disease
    March 2009 (Vol. 50 | No. 3 | Pages 449-452)

    Hartmut H.-J. Schmidt

  • Anti-HCV core antibody: A potential new marker of occult and otherwise serologically silent HCV infection
    February 2009 (Vol. 50 | No. 2 | Pages 244-246)

    Tomasz I. Michalak, Tram N.Q. Pham

  • Is family history of liver cancer a risk factor for hepatocellular carcinoma?
    February 2009 (Vol. 50 | No. 2 | Pages 247-248)

    Michael L. Volk, Anna S.F. Lok

  • Iron in NASH, chronic liver diseases and HCC: How much iron is too much?
    February 2009 (Vol. 50 | No. 2 | Pages 249-251)

    Antonello Pietrangelo

  • HBV protein as a double-barrel shot-gun targets epigenetic landscape in liver cancer
    February 2009 (Vol. 50 | No. 2 | Pages 252-255)

    Zdenko Herceg, Anupam Paliwal

  • Liver biopsy: The best, not the gold standard
    January 2009 (Vol. 50 | No. 1 | Pages 1-3)

    Pierre Bedossa, Fabrice Carrat

  • Towards the non-invasive diagnosis of cirrhosis: The nuts-cirrhosis connection
    January 2009 (Vol. 50 | No. 1 | Pages 4-6)

    Jaime Bosch

  • Settling the “score” with liver cancer
    January 2009 (Vol. 50 | No. 1 | Pages 7-9)

    Christopher Koh, T. Jake Liang

  • Hepatocellular cancer care: Cost is important but only one factor of disease burden
    January 2009 (Vol. 50 | No. 1 | Pages 10-12)

    Fasiha Kanwal, Hashem B. El-Serag

  • Are herbals as safe as their advocates believe?
    January 2009 (Vol. 50 | No. 1 | Pages 13-16)

    Leonard B. Seeff

2008

  • New light on anion exchangers in primary biliary cirrhosis
    December 2008 (Vol. 49 | No. 6 | Pages 881-883)

    Ulrich Beuers, Ronald P.J. Oude-Elferink

  • Treatment of the hepatitis B virus and hepatitis C virus co-infection: Still a challenge for the hepatologist
    November 2008 (Vol. 49 | No. 5 | Pages 677-679)

    Giovanni Raimondo, Carlo Saitta

  • Hepcidin in the management of patients with mild non-hemochromatotic iron overload: Fact or fiction?
    November 2008 (Vol. 49 | No. 5 | Pages 680-685)

    Dorine W. Swinkels, Joost P.H. Drenth

  • Branched-chain amino acids antagonism in patients with cirrhosis and a simulated upper GI bleed
    November 2008 (Vol. 49 | No. 5 | Pages 686-687)

    Fin Stolze Larsen

  • Is there discrimination in access to therapy for HCV patients?
    October 2008 (Vol. 49 | No. 4 | Pages 491-493)

    Silvio Garattini

  • Can genetic variations predict HCV treatment outcomes?
    October 2008 (Vol. 49 | No. 4 | Pages 494-497)

    Nazia Selzner, Ian McGilvray

  • Molecular tools and hepatocellular carcinoma: Adding help or confusion in liver transplantation?
    October 2008 (Vol. 49 | No. 4 | Pages 498-501)

    Eric Vibert, Didier Samuel

  • Resection or ablation of small hepatocellular carcinoma: What is the better treatment?
    October 2008 (Vol. 49 | No. 4 | Pages 502-504)

    Henrik Petrowsky, Ronald W. Busuttil

  • The role of re-infection in determining rates of spontaneous clearance after hepatitis C exposure
    September 2008 (Vol. 49 | No. 3 | Pages 305-307)

    Gail V. Matthews, Jason Grebely, Gregory J. Dore

  • PHES: One label, different goods?!
    September 2008 (Vol. 49 | No. 3 | Pages 308-312)

    Karin Weissenborn

  • Temporary portal vein embolization as a starter of liver regeneration
    September 2008 (Vol. 49 | No. 3 | Pages 313-315)

    Mickael Lesurtel, Jacques Belghiti

  • Telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in chronic hepatitis C patients
    August 2008 (Vol. 49 | No. 2 | Pages 157-159)

    Stefan Zeuzem

  • Tumor-specific marker genes for intrahepatic cholangiocarcinoma: Utility and mechanistic insight
    August 2008 (Vol. 49 | No. 2 | Pages 160-162)

    Boris Blechacz, Gregory J. Gores

  • Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials
    July 2008 (Vol. 49 | No. 1 | Pages 1-5)

    Pippa Newell, Augusto Villanueva, Josep M. Llovet

  • A symphony of techniques for liver cell therapy, only applicable to rats?
    July 2008 (Vol. 49 | No. 1 | Pages 6-8)

    Michael Ott

  • Monitoring antiviral resistance in patients receiving nucleos(t)ide analog therapies for hepatitis B: Which method should be used?
    June 2008 (Vol. 48 | No. 6 | Pages 892-894)

    Bulent Degertekin, Anna S. Lok

  • Combination therapy for chronic hepatitis B: Ready for prime time?
    May 2008 (Vol. 48 | No. 5 | Pages 687-691)

    Ira M. Jacobson

  • High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis
    May 2008 (Vol. 48 | No. 5 | Pages 692-694)

    Marina G. Silveira, Keith D. Lindor

  • Liver stiffness values in healthy subjects: Implications for clinical practice
    April 2008 (Vol. 48 | No. 4 | Pages 529-531)

    Jeremy F.L. Cobbold, Simon D. Taylor-Robinson

  • Potency of tenofovir in chronic hepatitis B: Mono or combination therapy?
    March 2008 (Vol. 48 | No. 3 | Pages 383-386)

    J.G.P. Reijnders, H.L.A. Janssen

  • TIPS is a cost effective alternative to surgical shunt as a rescue therapy for prevention of recurrent bleeding from esophageal varices
    March 2008 (Vol. 48 | No. 3 | Pages 387-390)

    Gennaro D’Amico, Angelo Luca

  • Hepatitis C infection: Dying with or from the infection?
    February 2008 (Vol. 48 | No. 2 | Pages 183-184)

    Hashem El-Serag, Jennifer R. Kramer

  • Predicting failure to control bleeding and mortality in acute variceal bleeding
    February 2008 (Vol. 48 | No. 2 | Pages 185-188)

    A.K. Burroughs, C.K. Triantos

  • Bio-artificial liver devices – Tentative, but promising progress
    February 2008 (Vol. 48 | No. 2 | Pages 189-191)

    Konrad L. Streetz

  • Healthcare should not be a vehicle for transmission of hepatitis C virus
    January 2008 (Vol. 48 | No. 1 | Pages 2-4)

    Miriam J. Alter

  • Treatment of hepatitis C in HIV-infected persons: A work in progress
    January 2008 (Vol. 48 | No. 1 | Pages 5-7)

    Mark Sulkowski

  • Hepatitis C core protein – The “core” of immune deception?
    January 2008 (Vol. 48 | No. 1 | Pages 8-11)

    Gyongyi Szabo, Angela Dolganiuc

2007

  • Steroids in recurrent hepatitis C following liver transplantation: Pitfall or panacea?
    December 2007 (Vol. 47 | No. 6 | Pages 741-743)

    Robert S. Brown

  • Thrombocytopenia in chronic liver disease: Lessons from transplanted patients
    November 2007 (Vol. 47 | No. 5 | Pages 625-629)

    Giacomo Laffi, Roberto Tarquini, Fabio Marra

  • Significance of viral status on prognosis after resection of hepatitis B virus related hepatocellular carcinoma
    November 2007 (Vol. 47 | No. 5 | Pages 630-631)

    Ronnie T.P. Poon

  • Treatment of chronic HCV in advanced liver disease: Unmet challenges, reason for optimism
    October 2007 (Vol. 47 | No. 4 | Pages 441-443)

    Geoffrey S. Jensen, James F. Trotter

  • Slimming at all costs: Herbalife®-induced liver injury
    October 2007 (Vol. 47 | No. 4 | Pages 444-446)

    Felix Stickel

  • Hepatocellular carcinoma in human immunodeficiency virus (HIV)-infected patients: Is it really different, and if so, why?
    October 2007 (Vol. 47 | No. 4 | Pages 447-450)

    Françoise Degos, Cristina Tural

  • NASH and thiazolidinediones: Not to be taken lightly
    October 2007 (Vol. 47 | No. 4 | Pages 451-453)

    Jean-François Dufour

  • Need for liver evaluation in polycystic ovary syndrome
    September 2007 (Vol. 47 | No. 3 | Pages 313-315)

    Enrico Carmina

  • Toll like receptor 7 and hepatitis C virus infection
    August 2007 (Vol. 47 | No. 2 | Pages 165-167)

    Michael Schultheiß, Robert Thimme

  • Induction of cerebral hyperemia by ammonia plus endotoxin: Does hyperammonemia unlock the blood–brain barrier?
    August 2007 (Vol. 47 | No. 2 | Pages 168-171)

    Rajiv Jalan, Jacques Bernuau

  • Non-invasive testing for Wilson disease: Revisiting the d-penicillamine challenge test
    August 2007 (Vol. 47 | No. 2 | Pages 172-173)

    Michael L. Schilsky

  • Ribavirin in combination therapy for HCV chronic infection in HIV patients: How to win the war after winning the first battle?
    July 2007 (Vol. 47 | No. 1 | Pages 1-3)

    Claude Souvignet, Marianne Maynard, Marie-Claude Gagnieu, Christian Trepo

  • Outcome of hepatitis C infection: Bleak or benign?
    July 2007 (Vol. 47 | No. 1 | Pages 4-6)

    Stephen D. Ryder

  • Anemia and clinical outcomes in hepatitis C
    July 2007 (Vol. 47 | No. 1 | Pages 7-9)

    Yves Benhamou

  • Critical flicker frequency: It is time to break down barriers surrounding minimal hepatic encephalopathy
    July 2007 (Vol. 47 | No. 1 | Pages 10-11)

    Manuel Romero-Gómez

  • Hepatitis C virus: The viral way to fatty liver
    June 2007 (Vol. 46 | No. 6 | Pages 985-987)

    Sophie Clément, Francesco Negro

  • Ribavirin in the treatment of recurrent hepatitis C after liver transplantation: Difficult to manage but essential for success
    June 2007 (Vol. 46 | No. 6 | Pages 988-991)

    Didier Samuel, Bruno Roche

  • Fatigue in cholestatic liver disease: Is it all in the mind?
    June 2007 (Vol. 46 | No. 6 | Pages 992-994)

    David E.J. Jones

  • Dangerous liaisons: Drug, host and the environment
    June 2007 (Vol. 46 | No. 6 | Pages 995-998)

    Guruprasad P. Aithal

  • Non-invasive tests for liver fibrosis: Encouraging or discouraging results?
    May 2007 (Vol. 46 | No. 5 | Pages 751-755)

    Andrew K. Burroughs, Evangelos Cholongitas

  • Tailoring antiviral therapy in chronic hepatitis B patients with lamivudine resistance
    May 2007 (Vol. 46 | No. 5 | Pages 756-758)

    Maurizia Rossana Brunetto

  • Technology evaluation: A critical step in the clinical utilization of novel diagnostic tests for liver fibrosis
    April 2007 (Vol. 46 | No. 4 | Pages 543-545)

    Nezam H. Afdhal, Michael Curry

  • Tumor suppressors in hepatocellular carcinoma: Many are called, but few are chosen
    April 2007 (Vol. 46 | No. 4 | Pages 546-548)

    Marie Annick Buendia

  • Ferritin, metabolic syndrome and NAFLD: Elective attractions and dangerous liaisons
    April 2007 (Vol. 46 | No. 4 | Pages 549-552)

    Paola Trombini, Alberto Piperno

  • In vitro veritas? The challenges of studying hepatitis C virus infectivity in a test tube
    March 2007 (Vol. 46 | No. 3 | Pages 355-358)

    Thomas von Hahn, Jane A. McKeating

  • Antiviral therapy in liver transplant recipients: Is SVR the only endpoint that matters?
    March 2007 (Vol. 46 | No. 3 | Pages 359-361)

    Alexander Kuo, Norah A. Terrault

  • Interventional radiology as a fine art
    March 2007 (Vol. 46 | No. 3 | Pages 362-364)

    Michel Beaugrand, Jean-Claude Trinchet

  • Antiviral therapy in HCV decompensated cirrhosis: To treat or not to treat?
    February 2007 (Vol. 46 | No. 2 | Pages 185-188)

    Miquel Navasa, Xavier Forns

  • Todralazine hepatotoxicity: A sting in the histone tail
    February 2007 (Vol. 46 | No. 2 | Pages 189-192)

    Ahmed M. Elsharkawy

  • Going towards more relevant cell culture models to study the in vitro replication of serum-derived hepatitis C virus and virus/host cell interactions?
    January 2007 (Vol. 46 | No. 1 | Pages 1-5)

    David Durantel, Fabien Zoulim

  • Does treatment with interferon-based therapy improve the natural history of chronic hepatitis B infection?
    January 2007 (Vol. 46 | No. 1 | Pages 6-8)

    George K.K. Lau

  • In the new area of noninvasive markers of hepatocellular carcinoma
    January 2007 (Vol. 46 | No. 1 | Pages 9-11)

    Valérie Paradis, Pierre Bedossa

2006

  • Genetic mutation in hepatic adenoma: Seeing is believing
    December 2006 (Vol. 45 | No. 6 | Pages 767-769)

    Pei-Jer Chen

  • “Return to sender, address unknown.…” Are variant addressins involved in PSC?
    November 2006 (Vol. 45 | No. 5 | Pages 633-635)

    Ronald Oude Elferink

  • Turning on the off switch: Regulation of anti-viral T cell responses in the liver by the PD-1/PD-L1 pathway
    October 2006 (Vol. 45 | No. 4 | Pages 468-472)

    Arash Grakoui, E. John Wherry, Holly L. Hanson, Christopher Walker, Rafi Ahmed

  • Endpoints for clinical trials on treatment of hepatitis C
    October 2006 (Vol. 45 | No. 4 | Pages 473-475)

    Hellan Kang, Anna S.F. Lok

  • Diagnosis of cholangiocarcinoma in patients with PSC: A sight on cytology
    October 2006 (Vol. 45 | No. 4 | Pages 476-479)

    E.S. Baskin-Bey, L.E. Moreno Luna, G.J. Gores

  • Autoimmune hepatitis in the elderly: What is the difference?
    October 2006 (Vol. 45 | No. 4 | Pages 480-482)

    Christian P. Strassburg, Michael P. Manns

  • HBeAg-negative chronic hepatitis B: From obscurity to prominence
    September 2006 (Vol. 45 | No. 3 | Pages 343-346)

    Emanuel K. Manesis

  • Involvement of the innate immune system in liver regeneration and injury
    September 2006 (Vol. 45 | No. 3 | Pages 347-349)

    Nelson Fausto

  • Early intrahepatic CD8 responses in HBV pathogenesis: A new piece of the puzzle
    August 2006 (Vol. 45 | No. 2 | Pages 169-171)

    Gabriele Missale

  • Antiviral effect of peginterferon alfa-2b and alfa-2a compared
    August 2006 (Vol. 45 | No. 2 | Pages 172-173)

    Peter L.M. Jansen, Henk W. Reesink

  • Predictions from a hard liver
    August 2006 (Vol. 45 | No. 2 | Pages 174-177)

    Jaime Bosch

  • T cell infiltration and prognosis in HCC patients
    August 2006 (Vol. 45 | No. 2 | Pages 178-181)

    Giorgio Parmiani, Andrea Anichini

  • Different types of liver progenitor cells and their niches
    July 2006 (Vol. 45 | No. 1 | Pages 1-4)

    Tania Roskams

  • Risk factors for hepatocellular carcinoma in HCV-cirrhosis: What we know and what is missing
    June 2006 (Vol. 44 | No. 6 | Pages 1013-1016)

    Giovanna Fattovich, Josep M. Llovet

  • Let's assume that hepatitis C reduces the cardiovascular risk in dialysis patients: Are there practical implications?
    May 2006 (Vol. 44 | No. 5 | Pages 837-838)

    Dario Cattaneo, Norberto Perico, Giuseppe Remuzzi

  • The paradox of Epstein–Barr virus-associated hepatitis
    May 2006 (Vol. 44 | No. 5 | Pages 839-841)

    Francesco Negro

  • HCV therapy in 2006: Down with ALT levels, in with awareness of co-existent metabolic syndrome
    April 2006 (Vol. 44 | No. 4 | Pages 624-626)

    Stephen A. Harrison

  • Immunosuppression and outcomes of patients transplanted for hepatitis C
    April 2006 (Vol. 44 | No. 4 | Pages 627-629)

    John R. Lake

  • The coming wave of HCV-related liver disease: Dilemmas and challenges
    March 2006 (Vol. 44 | No. 3 | Pages 441-443)

    Joseph F. Perz, Miriam J. Alter

  • Is the intraductal papillary mucinous neoplasia of the biliary tract a counterpart of pancreatic papillary mucinous neoplasm?
    February 2006 (Vol. 44 | No. 2 | Pages 249-250)

    Günter Klöppel, Markus Kosmahl

  • Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: A foray across diagnostic boundaries
    February 2006 (Vol. 44 | No. 2 | Pages 251-252)

    Albert J. Czaja

  • Treatment of lamivudine-resistant hepatitis B in HIV-infected persons: Is adefovir dipivoxil the answer?
    January 2006 (Vol. 44 | No. 1 | Pages 1-3)

    Chloe L. Thio

  • Treating patients with HCV genotype 1 and low viraemia: More than meets the eye
    January 2006 (Vol. 44 | No. 1 | Pages 4-7)

    Antonio Craxì, Calogero Cammà

  • Hepatocellular carcinoma in the United States. Lessons from a population-based study in Medicare recipients
    January 2006 (Vol. 44 | No. 1 | Pages 8-10)

    Maria Varela, Jordi Bruix

2005

  • Resistance to adefovir: A new challenge in the treatment of chronic hepatitis B
    December 2005 (Vol. 43 | No. 6 | Pages 920-923)

    Patrick Marcellin, Tarik Asselah

  • Pros and cons of TIPS for refractory ascites
    December 2005 (Vol. 43 | No. 6 | Pages 924-925)

    A.J. Sanyal

  • NAFLD treatment: Cognitive-behavioral therapy has entered the arena
    December 2005 (Vol. 43 | No. 6 | Pages 926-928)

    Giulio Marchesini, Alessandro Suppini, Gabriele Forlani

  • Rethinking hepatitis C viral kinetics: Insights into host-virus interactions in ‘difficult-to-treat’ groups and implications for novel treatment approaches
    November 2005 (Vol. 43 | No. 5 | Pages 748-750)

    Elaine Yeung, Raymond T. Chung

  • Adenovirus-mediated overexpression of activin βC subunit accelerates liver regeneration in partially hepatectomized rats
    November 2005 (Vol. 43 | No. 5 | Pages 751-753)

    Rebecca Taub

  • Mobilizing stem cells to repair liver after surgery: Dream or reality?
    November 2005 (Vol. 43 | No. 5 | Pages 754-756)

    Vincent Olivier Mallet, Hélène Gilgenkrantz

  • HCV natural history: The retrospective and prospective in perspective
    October 2005 (Vol. 43 | No. 4 | Pages 550-552)

    Harvey J. Alter

  • Mutagenic effects of ribavirin in vivo
    October 2005 (Vol. 43 | No. 4 | Pages 553-555)

    Alan S. Perelson, Ruy M. Ribeiro

  • Fourth Forum on Liver Transplantation Hepatocellular carcinoma: where are the controversies?
    October 2005 (Vol. 43 | No. 4 | Pages 556-557)

    Pierre-Alain Clavien

  • Divining the role of liver biopsy in hepatitis C
    September 2005 (Vol. 43 | No. 3 | Pages 374-376)

    Steven K. Herrine, Lawrence S. Friedman

  • Percutaneous ethanol injection for hepatocellular carcinoma: Alive or dead?
    September 2005 (Vol. 43 | No. 3 | Pages 377-380)

    Riccardo Lencioni, Josep M. Llovet

  • Adefovir-lamivudine combination therapy and hepatitis B viral kinetics
    August 2005 (Vol. 43 | No. 2 | Pages 200-202)

    David Mutimer

  • The questionable role of immunization against hepatitis B in HBV infected liver transplant patients
    August 2005 (Vol. 43 | No. 2 | Pages 203-206)

    Didier Samuel, Daniel Shouval

  • Mitochondrial hepatopathies
    August 2005 (Vol. 43 | No. 2 | Pages 207-209)

    Patrick F. Chinnery, Salvatore DiMauro

  • Noninvasive markers of hepatic fibrosis: Are they ready for prime time in the management of HIV/HCV co-infected patients?
    July 2005 (Vol. 43 | No. 1 | Pages 2-5)

    Marija Zeremski, Andrew H. Talal

  • VEGF-induced angiogenesis drives collateral circulation in portal hypertension
    July 2005 (Vol. 43 | No. 1 | Pages 6-8)

    Richard Moreau

  • Hereditary haemochromatosis: To screen or not to screen?
    July 2005 (Vol. 43 | No. 1 | Pages 9-10)

    John K. Olynyk, Debbie Trinder, Elizabeth Milward

  • Third Forum on Liver Transplantation Living donor liver transplantation. Who needs it? How to do it? Who should do it?
    July 2005 (Vol. 43 | No. 1 | Pages 11-12)

    Pierre-Alain Clavien

  • Chronic hepatitis C, depression and interferon
    June 2005 (Vol. 42 | No. 6 | Pages 788-789)

    Yves Horsmans

  • Developing concepts on MELD: delta and cutoffs
    June 2005 (Vol. 42 | No. 6 | Pages 790-792)

    Gennaro D'Amico

  • Treatment for hepatic encephalopathy: tips from TIPS?
    May 2005 (Vol. 42 | No. 5 | Pages 626-628)

    Marsha Y. Morgan, Piero Amodio

  • Refined tools for the treatment of hepatocellular carcinoma
    May 2005 (Vol. 42 | No. 5 | Pages 629-631)

    Bruno Sangro

  • Time-dependent events in natural history of occult hepatitis B virus infection: the importance of population-based long-term follow-up study with repeated measurements
    April 2005 (Vol. 42 | No. 4 | Pages 438-440)

    Chien-Jen Chen

  • The anhepatic phase of liver transplantation as a model for measuring the extra-hepatic replication of hepatitis C virus
    April 2005 (Vol. 42 | No. 4 | Pages 441-443)

    Gaëtana Di Liberto, Cyrille Féray

  • Coffee, liver enzymes, cirrhosis and liver cancer
    April 2005 (Vol. 42 | No. 4 | Pages 444-446)

    Carlo La Vecchia

  • Second Forum on Liver Transplantation Liver transplantation for hepatitis C: how to control the virus?
    April 2005 (Vol. 42 | No. 4 | Page 447)

    Pierre-Alain Clavien

  • Risks and benefits of antiretroviral therapy in HIV–HCV co-infected patients
    March 2005 (Vol. 42 | No. 3 | Pages 290-292)

    Marina Núñez, Vincent Soriano

  • Treatment of acute hepatitis C infection: more pieces of the puzzle?
    March 2005 (Vol. 42 | No. 3 | Pages 293-296)

    Amany Zekry, Keyur Patel, John G. McHutchison

  • Cholestatic hepatocellular injury: what do we know and how should we proceed
    March 2005 (Vol. 42 | No. 3 | Pages 297-300)

    Maria Eugenia Guicciardi, Gregory J. Gores

  • New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA
    March 2005 (Vol. 42 | No. 3 | Pages 302-308)

    Fabien Zoulim

  • The value and limitations of long-term nucleoside antiviral therapy in chronic hepatitis B
    February 2005 (Vol. 42 | No. 2 | Pages 158-162)

    Jules L. Dienstag

  • Paralysed monocytes in acute on chronic liver disease
    February 2005 (Vol. 42 | No. 2 | Pages 163-165)

    Charalambos Gustav Antoniades, Julia Wendon, Diego Vergani

  • Mushrooms, amatoxins and the liver
    February 2005 (Vol. 42 | No. 2 | Pages 166-169)

    Antoni Mas

  • Intestinal flora and bilirubin
    February 2005 (Vol. 42 | No. 2 | Pages 170-172)

    Claudio Tiribelli, J. Donald Ostrow

  • Editorial
    January 2005 (Vol. 42 | No. 1 | Page 1)

  • Cardiovascular involvement in patients with liver cirrhosis
    January 2005 (Vol. 42 | No. 1 | Pages 3-4)

    Diwakar Jain

  • Attempting to predict the unpredictable in acute liver injury
    January 2005 (Vol. 42 | No. 1 | Pages 5-6)

    John O'Grady

  • Angiogenesis and chronic inflammation; the potential for novel therapeutic approaches in chronic liver disease
    January 2005 (Vol. 42 | No. 1 | Pages 7-11)

    W.K. Lai, David H. Adams

  • NASH: a hidden and silent fibroser finally revealed?
    January 2005 (Vol. 42 | No. 1 | Pages 12-14)

    Vlad Ratziu, Thierry Poynard

  • First Forum on Liver Transplantation Liver transplantation in the year 2005: where do we stand?
    January 2005 (Vol. 42 | No. 1 | Page 15)

    Pierre-Alain Clavien

2004

  • Goodbye from Barcelona!
    December 2004 (Vol. 41 | No. 6 | Pages 893-895)

    Juan Rodés, Pere Ginès, Xavier Forns, Nicki van Berckel

  • Hepatic clearance of advanced glycation end products (AGEs)—myth or truth?
    December 2004 (Vol. 41 | No. 6 | Pages 1038-1040)

    Dmitri Svistounov, Bård Smedsrød

  • Liver involvement in cystic fibrosis: primary organ damage or innocent bystander?
    December 2004 (Vol. 41 | No. 6 | Pages 1041-1044)

    Carla Colombo, Pier Maria Battezzati

  • Enhanced TH1 cytokine production in hepatitis C virus-infected patients with mixed cryoglobulinemia: understanding the pathological issues
    December 2004 (Vol. 41 | No. 6 | Pages 1045-1049)

    Anna Linda Zignego

  • Sustained activation of epidermal growth factor receptor in cholangiocarcinoma: a potent therapeutic target?
    November 2004 (Vol. 41 | No. 5 | Pages 859-861)

    Hirohito Tsubouchi

  • Fibrosis progression after liver transplantation in patients with recurrent hepatitis C
    November 2004 (Vol. 41 | No. 5 | Pages 862-863)

    Cyrille Feray

  • Restoring balance to liver stem cell research
    October 2004 (Vol. 41 | No. 4 | Pages 673-676)

    Neil D. Theise

  • Out of control: hepatitis B reactivation by transarterial treatment of hepatocellular carcinoma
    September 2004 (Vol. 41 | No. 3 | Pages 482-484)

    Fritz von Weizsäcker, Hubert E. Blum

  • Older livers—should they be used for transplantation?
    September 2004 (Vol. 41 | No. 3 | Pages 485-487)

    Wolf Otto Bechstein

  • Induction therapy in chronic hepatitis C: déjà-vu with pegylated interferons?
    September 2004 (Vol. 41 | No. 3 | Pages 488-490)

    Stefan Zeuzem

  • Genetics of autoimmune and viral liver diseases; understanding the issues
    August 2004 (Vol. 41 | No. 2 | Pages 327-332)

    Peter T. Donaldson

  • Role of vascular endothelial growth factor on the invasive potential of hepatocellular carcinoma
    August 2004 (Vol. 41 | No. 2 | Pages 333-335)

    Shigeki Arii

  • Gene expression profiles in hepatocellular carcinoma: not yet there
    August 2004 (Vol. 41 | No. 2 | Pages 336-339)

    Josep M. Llovet, Elisa Wurmbach

  • Microvascular graft dysfunction
    August 2004 (Vol. 41 | No. 2 | Pages 340-343)

    Charles Balabaud, Antonio Sa Cunha, Paulette Bioulac-Sage

  • Protein restriction in hepatic encephalopathy: necessary evil or illogical dogma?
    July 2004 (Vol. 41 | No. 1 | Pages 147-148)

    Kevin D. Mullen, Srinivasan Dasarathy

  • The future of fatty livers
    July 2004 (Vol. 41 | No. 1 | Pages 149-151)

    Carmen Peralta, Joan Roselló-Catafau

  • Acute liver failure: avoidance of deleterious cofactors and early specific medical therapy for the liver are better than late intensive care for the brain
    July 2004 (Vol. 41 | No. 1 | Pages 152-155)

    Jacques Bernuau

  • The role of hepatic stellate cells in liver regeneration
    June 2004 (Vol. 40 | No. 6 | Pages 1023-1026)

    Charles Balabaud, Paulette Bioulac-Sage, Alexis Desmoulière

  • The cirrhotic hepatocyte: navigating between Scylla and Charybdis
    June 2004 (Vol. 40 | No. 6 | Pages 1027-1029)

    Han Moshage

  • Interferon-α for hepatitis C: antiviral or immunotherapy?
    June 2004 (Vol. 40 | No. 6 | Pages 1030-1031)

    Helmut M Diepolder

  • Optimizing PEG-interferon and ribavirin combination therapy for patients infected with HCV-2 or HCV-3: is the puzzle completed?
    June 2004 (Vol. 40 | No. 6 | Pages 1032-1035)

    Alfredo Alberti

  • NASH: are genes blowing the hits?
    May 2004 (Vol. 40 | No. 5 | Pages 853-856)

    Fabio Marra

  • Primary sclerosing cholangitis and biliary malignancy: a glimmer of hope?
    May 2004 (Vol. 40 | No. 5 | Pages 857-859)

    Olivier Chazouillères

  • Rusty notions of cell injury
    April 2004 (Vol. 40 | No. 4 | Pages 696-698)

    John J. Lemasters

  • Changing faces—natural course and treatment of hepatitis C after liver transplantation
    April 2004 (Vol. 40 | No. 4 | Pages 699-701)

    Matthias J. Bahr, Michael P. Manns

  • Hepatitis C virus and liver steatosis: when fat is not beautiful
    March 2004 (Vol. 40 | No. 3 | Pages 533-535)

    Francesco Negro

  • Monitoring response to antiviral treatment by serum hepatitis C virus core antigen: too early to take shortcuts?
    March 2004 (Vol. 40 | No. 3 | Pages 536-538)

    Mario U Mondelli

  • Infection, inflammation and hepatic encephalopathy, synergism redefined
    February 2004 (Vol. 40 | No. 2 | Pages 327-330)

    Andres T Blei

  • On the origin of stellate cells: mesodermal, endodermal or neuro-ectodermal?
    February 2004 (Vol. 40 | No. 2 | Pages 331-334)

    Albert Geerts

  • Sensitizing to apoptosis—sharpening the medical sword
    February 2004 (Vol. 40 | No. 2 | Pages 335-336)

    Marcus Schuchmann, Peter R Galle

  • The promise of lentiviral gene therapy for liver cancer
    February 2004 (Vol. 40 | No. 2 | Pages 337-340)

    Antonia Follenzi, Sanjeev Gupta

  • The fourth year in Barcelona
    January 2004 (Vol. 40 | No. 1 | Page 1)

    Pere Ginès, Juan Rodés

  • MAGE antigens: therapeutic targets in hepatocellular carcinoma?
    January 2004 (Vol. 40 | No. 1 | Pages 155-158)

    Pablo Sarobe, Esperanza Feijoó, Carlos Alfaro, Guillermo Mazzolini, Ignacio Melero

  • The growing evidence that renal function should be improved in patients with cirrhosis and hepatorenal syndrome before liver transplantation
    January 2004 (Vol. 40 | No. 1 | Pages 159-161)

    Richard Moreau

2003

  • Intrahepatic T cell survival versus death: which one prevails and why?
    December 2003 (Vol. 39 | No. 6 | Pages 1070-1071)

    Wajahat Z Mehal

  • Decreasing hepatic vascular tone by liver-specific NO donors: wishful thinking or a promising reality?
    December 2003 (Vol. 39 | No. 6 | Pages 1072-1075)

    Jaime Bosch

  • The tightrope of therapeutic suppression of active transforming growth factor-β: high enough to fall deeply?
    November 2003 (Vol. 39 | No. 5 | Pages 856-859)

    Axel M Gressner, Ralf Weiskirchen

  • Cytochrome P450 2A6 meets P450 2D6: an enigma of viral infections and autoimmunity
    November 2003 (Vol. 39 | No. 5 | Pages 860-863)

    Dimitrios-Petrou Bogdanos, Ian G McFarlane

  • ABC transporter regulation by bile acids: where PXR meets FXR
    October 2003 (Vol. 39 | No. 4 | Pages 628-630)

    Gerd A Kullak-Ublick

  • Antiviral T-cell responses and therapy in chronic hepatitis B
    October 2003 (Vol. 39 | No. 4 | Pages 631-634)

    Nadia Alatrakchi, Margaret James Koziel

  • Prevalence of hepatitis C virus infection in porphyria cutanea tarda
    October 2003 (Vol. 39 | No. 4 | Pages 635-638)

    Silvia Fargion, Anna Ludovica Fracanzani

  • Atrial natriuretic peptide (ANP) preconditioning: what is the relevance of the antiapoptotic effects?
    September 2003 (Vol. 39 | No. 3 | Pages 428-430)

    Jean Gugenheim

  • Progenitor cell involvement in cirrhotic human liver diseases: from controversy to consensus
    September 2003 (Vol. 39 | No. 3 | Pages 431-434)

    Tania Roskams

  • Treatment of patients with decompensated post-hepatitis C cirrhosis before liver transplantation: strategy to prevent hepatitis C virus (HCV) recurrence?
    September 2003 (Vol. 39 | No. 3 | Pages 435-436)

    Jean-Pierre Zarski, Marie-Noëlle Hilleret

  • Hepatocellular carcinoma: beyond screening
    August 2003 (Vol. 39 | No. 2 | Pages 269-271)

    Morris Sherman

  • Quality of life and cognitive function in chronic hepatitis C – what to measure?
    August 2003 (Vol. 39 | No. 2 | Pages 272-274)

    Daniel M Forton, Howard C Thomas, Simon D Taylor-Robinson

  • Pathologist's perspective on liver needle biopsy size?
    August 2003 (Vol. 39 | No. 2 | Pages 275-277)

    A.J Demetris, Kris Ruppert

  • Transplantation in Journal of Hepatology
    July 2003 (Vol. 39 | No. 1 | Page 1)

    Juan Rodés

  • Ursodeoxycholic acid for primary biliary cirrhosis: treat early to slow progression
    July 2003 (Vol. 39 | No. 1 | Pages 112-114)

    Gustav Paumgartner

  • Biliary cholesterol secretion: more lessons from plants?
    June 2003 (Vol. 38 | No. 6 | Pages 843-846)

    Bruno Stieger

  • Transcriptional profiling of liver regeneration: new approaches to an old trick!
    June 2003 (Vol. 38 | No. 6 | Pages 847-849)

    C Mitchell, H Gilgenkrantz

  • Towards an improved and cost-saving prophylaxis of hepatitis B virus recurrence after liver transplantation?
    June 2003 (Vol. 38 | No. 6 | Pages 850-852)

    Fabien Zoulim

  • Treatment options for chronic hepatitis B not responding to interferon
    June 2003 (Vol. 38 | No. 6 | Pages 853-855)

    Stephanos J Hadziyannis

  • Is nitric oxide the ultimate mediator in hepatopulmonary syndrome?
    May 2003 (Vol. 38 | No. 5 | Pages 668-670)

    Giovanni Rolla

  • Cholangiocarcinoma: preventing invasion as anti-cancer strategy
    May 2003 (Vol. 38 | No. 5 | Pages 671-673)

    Gregory J Gores

  • Expansion of CD5+ B-cell overexpressing CD81 in HCV infection: towards better understanding the link between HCV infection, B-cell activation and lymphoproliferation
    May 2003 (Vol. 38 | No. 5 | Pages 674-676)

    Eli Zuckerman

  • Chronic HCV infection and the clonality of intrahepatic T cells
    May 2003 (Vol. 38 | No. 5 | Pages 677-680)

    Michelina Nascimbeni, Barbara Rehermann

  • Anti-tumor necrosis factor-alpha therapy in severe alcoholic hepatitis: are large randomized trials still possible?
    April 2003 (Vol. 38 | No. 4 | Pages 518-520)

    Thierry Poynard, Dominique Thabut, Ariane Chryssostalis, Julien Taieb, Vlad Ratziu

  • Iron overload, inflammation and fibrosis in genetic haemochromatosis
    April 2003 (Vol. 38 | No. 4 | Pages 521-525)

    Stefan G Hübscher

  • Lamivudine resistant occult HBV: implications for public health?
    April 2003 (Vol. 38 | No. 4 | Pages 526-528)

    Scott Bowden, Angeline Bartholomeusz, Stephen Locarnini

  • HCV carriers with persistently normal aminotransferase levels: normal does not always mean healthy
    April 2003 (Vol. 38 | No. 4 | Pages 529-532)

    Claudio Puoti

  • Rating fibrosis progression in chronic liver diseases
    March 2003 (Vol. 38 | No. 3 | Pages 357-360)

    William M.C Rosenberg

  • Evaluation and follow-up of patients with cirrhosis and oesophageal varices
    March 2003 (Vol. 38 | No. 3 | Pages 361-363)

    Roberto de Franchis

  • Prognostic factors after resection of hepatocellular carcinoma: are there landmarks in the wild forest?
    February 2003 (Vol. 38 | No. 2 | Pages 237-239)

    Jean-Nicolas Vauthey, Gregory Y Lauwers

  • Assessment of liver biopsies in chronic hepatitis: how is it best done?
    February 2003 (Vol. 38 | No. 2 | Pages 240-242)

    Peter J Scheuer

  • The third year in Barcelona
    January 2003 (Vol. 38 | No. 1 | Page 1)

    Juan Rodés

  • Extracorporeal liver support with MARS in liver failure: has it a role in the treatment of severe alcoholic hepatitis?
    January 2003 (Vol. 38 | No. 1 | Pages 104-106)

    Philippe Ichai, Didier Samuel

2002

  • Trials of opiate antagonists for the pruritus of cholestasis: primary efficacy endpoints and opioid withdrawal-like reactions
    December 2002 (Vol. 37 | No. 6 | Pages 863-865)

    E.Anthony Jones

  • Acute, serious drug-induced liver injury
    November 2002 (Vol. 37 | No. 5 | Pages 675-677)

    Christian Gluud

  • Are nitric oxide synthases new players in the pathophysiology of fulminant hepatic failure?
    November 2002 (Vol. 37 | No. 5 | Pages 678-680)

    Richard Moreau

  • Human herpesvirus-6 and liver transplantation
    November 2002 (Vol. 37 | No. 5 | Pages 681-683)

    Hans J Schlitt, Liwei Shi

  • Multifactorial gut barrier failure in cirrhosis and bacterial translocation: working out the role of probiotics and antioxidants
    October 2002 (Vol. 37 | No. 4 | Pages 523-526)

    Agustı́n Albillos, Antonio de la Hera

  • Non-selective beta-blockers in the prevention of first variceal bleeding. Is there any definite alternative?
    September 2002 (Vol. 37 | No. 3 | Pages 393-395)

    Juan Carlos Garcia-Pagan

  • Influence of C4A deficiency on nonresponse to HBsAg vaccination: a new immune response gene
    September 2002 (Vol. 37 | No. 3 | Pages 396-399)

    David R. Milich

  • Canalicular bile formation: beyond single transporter functions
    August 2002 (Vol. 37 | No. 2 | Pages 272-273)

    Peter J. Meier

  • Ribavirin and interferon combination for recurrent post-transplant hepatitis C: which benefit beyond 6 months?
    August 2002 (Vol. 37 | No. 2 | Pages 274-276)

    Thierry Bizollon, Christian Trepo

  • Hepatitis B virus viral dynamics: effects of drug dose and baseline alanine aminotransferase
    August 2002 (Vol. 37 | No. 2 | Pages 277-279)

    Ruy M Ribeiro, Alan S Perelson

  • Towards a bank of cryopreserved hepatocytes: which cell to freeze?
    July 2002 (Vol. 37 | No. 1 | Pages 145-146)

    Yaron Ilan

  • It could have been something they ate – functional food and the treatment of liver cancer
    July 2002 (Vol. 37 | No. 1 | Pages 147-150)

    Nathan M Bass

  • Favourable and disappointing lessons from viral kinetics
    July 2002 (Vol. 37 | No. 1 | Pages 151-153)

    Stefan Zeuzem

  • Dead or alive – NF-κB, the guardian which tips the balance
    June 2002 (Vol. 36 | No. 6 | Pages 827-828)

    Marcus Schuchmann, Peter R. Galle

  • Is liver transplantation an appropriate treatment for acute alcoholic hepatitis?
    June 2002 (Vol. 36 | No. 6 | Pages 829-831)

    Michael R. Lucey

  • Small duct primary sclerosing cholangitis
    May 2002 (Vol. 36 | No. 5 | Pages 692-694)

    Roger W Chapman

  • Liver regeneration: with a little help from marrow
    May 2002 (Vol. 36 | No. 5 | Pages 695-697)

    Nicolas Ferry, Michelle Hadchouel

  • Alcoholic hepatitis – glucocorticosteriods or not?
    April 2002 (Vol. 36 | No. 4 | Pages 547-548)

    Erik Christensen

  • Clinical utility in quantifying serum HBV DNA levels using PCR assays
    April 2002 (Vol. 36 | No. 4 | Pages 549-551)

    Chi-Jen Chu, Anna Suk-Fong Lok

  • Primary sclerosing cholangitis: neoplastic potential in bile ducts, colon and the pancreas?
    March 2002 (Vol. 36 | No. 3 | Pages 433-434)

    Adolf Stiehl

  • Reduced quality of life in hepatitis C – is it all in the head?
    March 2002 (Vol. 36 | No. 3 | Pages 435-438)

    Daniel M Forton, Simon D Taylor-Robinson, Howard C Thomas

  • Endoscopic treatment for primary sclerosing cholangitis?
    February 2002 (Vol. 36 | No. 2 | Pages 278-279)

    Erik Schrumpf, Kirsten Muri Boberg

  • Interferon alpha therapy in HBeAg-negative chronic hepatitis B: new data in support of long-term efficacy
    February 2002 (Vol. 36 | No. 2 | Pages 280-282)

    Stephanos J Hadziyannis

  • The second year in Barcelona
    January 2002 (Vol. 36 | No. 1 | Pages 1-2)

    Juan Rodés

  • The liver is the main site for metabolism of circulating advanced glycation end products
    January 2002 (Vol. 36 | No. 1 | Pages 123-125)

    Seikoh Horiuchi

  • Antibodies and primary biliary cirrhosis – piecing together the jigsaw
    January 2002 (Vol. 36 | No. 1 | Pages 126-129)

    James Neuberger

2001

  • Why are patients with liver disease jaundiced? ATP-binding cassette transporter expression in human liver disease
    December 2001 (Vol. 35 | No. 6 | Pages 811-813)

    Peter L.M. Jansen, Tania Roskams

  • A new route to apoptosis in hepatitis C virus infection
    December 2001 (Vol. 35 | No. 6 | Pages 814-815)

    Luigi Muratori, Davide Gibellini

  • Salvage transjugular intrahepatic portosystemic shunt for uncontrolled variceal bleeding in patients with decompensated cirrhosis
    November 2001 (Vol. 35 | No. 5 | Pages 590-597)

    Daniel Azoulay, Denis Castaing, Pietro Majno, Faouzi Saliba, Philippe Ichaı̈, Allaoua Smail, Valérie Delvart, Monzer Danaoui, Didier Samuel, Henri Bismuth

  • Images of the brain in chronic liver failure
    November 2001 (Vol. 35 | No. 5 | Pages 661-662)

    Roger F Butterworth

  • Heat shock: a barrier to hepatic ischemic injury
    November 2001 (Vol. 35 | No. 5 | Pages 663-665)

    José M Mato, Fernando J Corrales, Matias A Avila

  • FIC1: another bile salt carrier within the enterohepatic circulation?
    October 2001 (Vol. 35 | No. 4 | Pages 522-524)

    Bruno Stieger

  • Pronucleating proteins in bile – a myth?
    October 2001 (Vol. 35 | No. 4 | Pages 525-526)

    Sum P Lee, Cynthia W Ko

  • Amantadine for chronic hepatitis C: a magic bullet or yet another dead duck?
    October 2001 (Vol. 35 | No. 4 | Pages 527-530)

    Antonio Craxı̀, Oreste Lo Iacono

  • The natural history of primary biliary cirrhosis: of genes and cooperation
    September 2001 (Vol. 35 | No. 3 | Pages 412-415)

    M.Eric Gershwin

  • Cytokines and neuroendocrine dysregulation in obstructive cholestasis: pathophysiological implications
    September 2001 (Vol. 35 | No. 3 | Pages 416-418)

    Mark Gordon Swain

  • Lamivudine-interferon combination therapy for chronic hepatitis B: further support but no conclusive evidence
    September 2001 (Vol. 35 | No. 3 | Pages 419-420)

    Solko Walle Schalm

  • Liver biopsy in elevated liver functions tests? An old question revisited
    August 2001 (Vol. 35 | No. 2 | Pages 290-294)

    Leonardo Bianchi

  • The pros and cons of gene expression analysis by microarrays
    August 2001 (Vol. 35 | No. 2 | Pages 295-296)

    Albert K Groen

  • Unravelling complexity – the scientific basis of genetic predisposition in autoimmune liver disease
    July 2001 (Vol. 35 | No. 1 | Pages 127-129)

    Ulrich Spengler

  • Alcoholic liver disease: a matter of hormones?
    July 2001 (Vol. 35 | No. 1 | Pages 130-133)

    Han Moshage

  • Heme oxygenase: protective enzyme or portal hypertensive molecule?
    June 2001 (Vol. 34 | No. 6 | Pages 936-939)

    Richard Moreau

  • The inflammatory basis of intracranial hypertension in acute liver failure
    June 2001 (Vol. 34 | No. 6 | Pages 940-942)

    Rajiv Jalan, Roger Williams

  • Liver transplantation and hepatitis B virus infection: the situation seems to be under control, but the virus is still there
    June 2001 (Vol. 34 | No. 6 | Pages 943-945)

    Didier Samuel

  • Caveats concerning hepatopulmonary syndrome
    May 2001 (Vol. 34 | No. 5 | Pages 756-758)

    Michael J Krowka

  • Vascular endothelial growth factor and liver regeneration
    May 2001 (Vol. 34 | No. 5 | Pages 759-761)

    Hendrik Reynaert, Marcela Chavez, Albert Geerts

  • Serial liver biopsies: a gateway into understanding the long-term health of the liver allograft
    May 2001 (Vol. 34 | No. 5 | Pages 762-763)

    Michael R Lucey

  • Progression of fibrosis in chronic liver diseases: time to tally the score
    May 2001 (Vol. 34 | No. 5 | Pages 764-767)

    Massimo Pinzani, Roberto G Romanelli, Sabrina Magli

  • Alphafetoprotein: an obituary
    April 2001 (Vol. 34 | No. 4 | Pages 603-605)

    Morris Sherman

  • Chemoprevention of hepatocellular carcinoma in hepatitis C virus-related cirrhosis: first, eliminate the virus
    April 2001 (Vol. 34 | No. 4 | Pages 606-609)

    Dominique-Charles Valla, Françoise Degos

  • Hepatic encephalopathy and nitric oxide
    April 2001 (Vol. 34 | No. 4 | Pages 610-612)

    Freimut Schliess, Dieter Häussinger

  • New concepts in bilirubin neurotoxicity and the need for studies at clinically relevant bilirubin concentrations
    March 2001 (Vol. 34 | No. 3 | Pages 467-470)

    J.Donald Ostrow, Claudio Tiribelli

  • Occult hepatitis B virus infection and liver disease: fact or fiction?
    March 2001 (Vol. 34 | No. 3 | Pages 471-473)

    Giovanni Raimondo

  • Apoptosis in alcoholic hepatitis: a novel therapeutic target?
    February 2001 (Vol. 34 | No. 2 | Pages 330-333)

    C.P. Day

  • Mitochondria: important target for drug toxicity?
    February 2001 (Vol. 34 | No. 2 | Pages 334-336)

    Stephan Krähenbühl

  • Post-liver transplantation osteoporosis
    February 2001 (Vol. 34 | No. 2 | Pages 337-338)

    Angela M. Cheung

  • Cholesterol and cholestasis: a lesson from the Mdr2 (−/−) mouse
    February 2001 (Vol. 34 | No. 2 | Pages 339-341)

    Michael Fuchs, Eduard F Stange

  • The first year in Barcelona
    January 2001 (Vol. 34 | No. 1 | Pages 2-3)

    Juan Rodés

  • Bioencapsulated hepatocytes for experimental liver support
    January 2001 (Vol. 34 | No. 1 | Pages 148-149)

    Thomas Ming Swi Chang

  • Bacterial translocation: cause or consequence of decompensation in cirrhosis?
    January 2001 (Vol. 34 | No. 1 | Pages 150-155)

    Guadalupe Garcı́a-Tsao

  • Dendritic cells: regulators of hepatic immunity or tolerance?
    January 2001 (Vol. 34 | No. 1 | Pages 156-160)

    Derek G Doherty, Cliona O'Farrelly

  • De novo tumours after liver transplantation in adults. What is the actual risk?
    January 2001 (Vol. 34 | No. 1 | Pages 161-164)

    Christophe Duvoux

2000

  • Assessing causality in drug-induced liver injury
    December 2000 (Vol. 33 | No. 6 | Pages 1003-1005)

    William M. Lee

  • Hepatocellular carcinoma and the art of prognostication
    December 2000 (Vol. 33 | No. 6 | Pages 1006-1008)

    Philip Johnson, Jordi Bruix

  • Is universal vaccination against hepatitis B sufficient for control of HBV infection? Lessons from the immunization campaign in Italy
    December 2000 (Vol. 33 | No. 6 | Pages 1009-1011)

    Daniel Shouval

  • Fetal microchimerism: an aetiological factor in primary biliary cirrhosis?
    November 2000 (Vol. 33 | No. 5 | Pages 834-837)

    David EJ Jones

  • Prions in activated hepatic stellate cells: not a surprise after all
    November 2000 (Vol. 33 | No. 5 | Pages 838-841)

    Hendrik Reynaert, Alastair Burt, Albert Geerts

  • Novel strains of hepatitis E virus identified from humans and other animal species: is hepatitis E a zoonosis?
    November 2000 (Vol. 33 | No. 5 | Pages 842-845)

    Xiang-Jin Meng

  • The role of magnetic resonance cholangiography in primary sclerosing cholangitis
    October 2000 (Vol. 33 | No. 4 | Pages 659-660)

    Masoom A. Haider, Patrice M. Bret

  • Diagnosis of primary sclerosing cholangitis - autoimmune hepatitis overlap syndrome: to score or not to score?
    October 2000 (Vol. 33 | No. 4 | Pages 661-663)

    Olivier Chazouillères

  • Combination therapy in naïve patients with chronic hepatitis C: more value for the money
    October 2000 (Vol. 33 | No. 4 | Pages 664-666)

    Raymond S. Koff

  • Jaundice, genes and promoters
    September 2000 (Vol. 33 | No. 3 | Pages 476-479)

    Christian P. Strassburg, Michael P. Manns

  • Mycophenolate mofetil - a new treatment for autoimmune hepatitis?
    September 2000 (Vol. 33 | No. 3 | Pages 480-481)

    Anil Dhawan, Giorgina Mieli-Vergani

  • New pieces to the hepatitis C treatment puzzle
    September 2000 (Vol. 33 | No. 3 | Pages 482-484)

    Ola Weiland

  • It's swell to have ATP in the liver
    August 2000 (Vol. 33 | No. 2 | Pages 323-325)

    Jonathan A Dranoff, Michael H Nathanson

  • Antibodies to soluble liver antigen: specific marker of autoimmune hepatitis
    August 2000 (Vol. 33 | No. 2 | Pages 326-328)

    Michael P. Manns

  • Lamivudine treatment in patients with decompensated hepatitis B cirrhosis: for whom and when?
    August 2000 (Vol. 33 | No. 2 | Pages 329-332)

    Robert J. Fontana, Anna S.F. Lok

  • Studies of genetic defects in hepatocellular carcinoma: recent outcomes and new challenges
    July 2000 (Vol. 33 | No. 1 | Pages 152-156)

    Pascal Pineau, Marie Annick Buendia

  • TT virus - highly prevalent, but still in search of a disease
    July 2000 (Vol. 33 | No. 1 | Pages 157-159)

    Nikolai V. Naoumov

  • Alcohol-induced fatty liver and inflammation: where do Kupffer cells act?
    June 2000 (Vol. 32 | No. 6 | Pages 1026-1030)

    Alessandro Casini

  • Recombinant adenoassociated virus in cancer gene therapy
    June 2000 (Vol. 32 | No. 6 | Pages 1031-1034)

    Chandan Guha, Namita Roy Chowdhury, Jayanta Roy Chowdhury

  • “;What's in a name?” Improving the care of cirrhotics
    May 2000 (Vol. 32 | No. 5 | Pages 859-861)

    Alan H. Lockwood

  • Iron, friend or foe? “Freedom” makes the difference
    May 2000 (Vol. 32 | No. 5 | Pages 862-864)

    Antonello Pietrangelo

  • Ursodeoxycholic acid for primary biliary cirrhosis: lessons from the pastissues for the future
    April 2000 (Vol. 32 | No. 4 | Pages 685-688)

    Renée Eugénie Poupon

  • The liver: a large endocrine gland
    March 2000 (Vol. 32 | No. 3 | Pages 505-507)

    Yaacov Baruch

1999

  • Phosphomannose isomerase deficiency as a cause of congenital hepatic fibrosis and protein-losing enteropathy
    September 1999 (Vol. 31 | No. 3 | Pages 557-560)

    Tom J.de Koning, Lambertus Dorland, Gerard P.van Berge Henegouwen

  • The use of endoscopic band ligation for the prophylaxis of variceal haemorrhage
    September 1999 (Vol. 31 | No. 3 | Pages 561-562)

    Peter C. Hayes

  • TNF gene polymorphisms in primary biliary cirrhosis: a critical appraisal
    August 1999 (Vol. 31 | No. 2 | Pages 366-368)

    Peter T. Donaldson

  • Ceramide-mediated apoptosis of hepatocytes in vivo: a matter of the nucleus?
    July 1999 (Vol. 31 | No. 1 | Pages 161-164)

    Dick Hoekstra

  • The direct interplay between HCV NS5A protein and interferon transduction signal: from clinical to basic science
    June 1999 (Vol. 30 | No. 6 | Pages 1152-1154)

    Christian Brechot

  • Role of S-adenosyl-L-methionine in the treatment of liver diseases
    June 1999 (Vol. 30 | No. 6 | Pages 1155-1159)

    Charles S Lieber

  • Endotoxemia: an unnecessary but aggravating condition in portal hypertension?
    June 1999 (Vol. 30 | No. 6 | Pages 1160-1162)

    Philippe Sogni, Richard Moreau, Didier Lebrec

  • Intravenous albumin with diuretics: protean lessons to be learnt?
    April 1999 (Vol. 30 | No. 4 | Pages 727-730)

    Laurance Blendis, Florence Wong

  • Complications of cirrhosis: is endothelium guilty?
    March 1999 (Vol. 30 | No. 3 | Pages 532-535)

    Giacomo Laffi, Fabio Marra

  • Genetics of tumour necrosis factor (TNF) in autoimmune liver diseases: red hot or red herring?
    February 1999 (Vol. 30 | No. 2 | Pages 331-333)

    A.Gerry Wilson